Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Docrates Cancer Center

2 abstracts

Abstract
Intravenous delivery of oncolytic adenovirus TILT-123 results in systemic tumor transduction and accumulation of lymphocytes.
Org: Cancer Gene Therapy Group, Docrates Cancer Center, National Center for Cancer Immune Therapy, Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland,
Abstract
PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.
Org: TILT Biotherapeutics, Mayo Clinic, Docrates Cancer Center, Cancer Gene Therapy Group, Merck & Co., Inc.,